Form 4: Theravance Biopharma Director O'Connor Acquires Shares and Options
SEC Form 4 Filing
Director Donal O'Connor reports acquisition of shares and options in Theravance Biopharma, Inc.
Summary
- On May 19, 2025, Donal O'Connor, a director of Theravance Biopharma, Inc., acquired 10,649 ordinary shares at $0 and disposed of 74,204 ordinary shares.
- O'Connor also acquired 24,258 share options with an exercise price of $9.39, exercisable from May 19, 2025, and expiring on May 18, 2035.
- Following these transactions, O'Connor beneficially owns 24,258 derivative securities.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing detailing changes in beneficial ownership. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about transactions.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in the biopharmaceutical industry. Monitoring such filings can provide insights into management's perspective on the company's value and prospects.
Stakeholder Impact
- The transactions may be of interest to shareholders as they reflect the actions of a company director.
Key Dates
| Date | Description |
|---|---|
| 05/19/2025 | Date of earliest transaction: Acquisition of shares and options, disposition of shares. |
| 05/19/2025 | Share options exercisable from this date. |
| 05/18/2035 | Share options expiration date. |
| 05/21/2025 | Date of signature by Attorney-in-Fact. |
Keywords
Theravance Biopharma, TBPH, Form 4, Beneficial Ownership, Director, O'Connor, Share Options, Ordinary Shares, Acquisition, Disposition
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.